Pulmonary Drug Delivery Systems Market Size, Share, and Trends

Pulmonary Drug Delivery Systems Market (By Product: Dry Powder Inhalers, Nebulizers, Metered Dose Inhalers, and Accessories; By Indication: COPD, Asthma, Cystic Fibrosis, Allergic Rhinitis, and Others; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and E-Commerce) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

  • Last Updated : October 2023
  • Report Code : 1502
  • Category : Healthcare

The global pulmonary drug delivery systems market was valued at US$ 51 billion in 2022 and is expected to reach over US$ 87.53 billion by 2032, growing at a noteworthy CAGR of 5.60% from 2023 to 2032.

Pulmonary Drug Delivery Systems Market Size 2023 to 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare


Pulmonary Drug Delivery Systems Market Size in the U.S. 2023 To 2032

The U.S. pulmonary drug delivery systems market accounted for US$ 9.49 billion in 2022 and is predicted to grow around US$ 16.43 billion by 2032, growing at a CAGR of 5.70% from 2023 to 2032.

U.S. Pulmonary Drug Delivery Systems Market Size 2023 To 2032

North America held the major market share in 2022. The increased prevalence of the pulmonary diseases in US have resulted in an increased demand for the pulmonary drug delivery systems. According to the American Lung Association, around 16.4 million people in US were diagnosed with some type of COPD such as emphysema, chronic bronchitis, and COPD. As per the Asthma and Allergy Foundation of America, around 25 million people were suffering from asthma in 2018 in US. Therefore, the increased prevalence of pulmonary diseases coupled with the increased awareness regarding the management of chronic conditions and high healthcare expenditure are the major factors that resulted in the growth of North America pulmonary drug delivery systems market.

Asia Pacific is poised to grow at the highest CAGR during the forecast period. The rapid industrialization and urbanization in the region is resulting in increasing pollution levels. The increased pollution in the air is a major cause of the pulmonary diseases. Moreover, higher mortality rates in this region due to the pulmonary diseases is expected to drive the demand for the pulmonary drug delivery systems. According to the WHO, around 80% of the death due to COPD occurs in the low and middle income countries. Therefore, the demand for the pulmonary drug delivery systems is projected to grow rapidly in Asia Pacific.

Growth Factors

Pulmonary drug delivery system is a targeted drug delivery in which a part of the drug is directed towards the targeted site or the respiratory tract. Simply, the pulmonary drug delivery systems is a device used for administration of drugs through the pulmonary route for the treatment of various respiratory diseases. The rising prevalence of respiratory diseases such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis is the primary reason behind the burgeoning demand for the pulmonary drug delivery systems across the globe. According to the World Health Organization, COPD caused around 3.23 million deaths in 2019 and it was the third leading cause of death across the globe. Moreover, around 262 million people across the globe were affected with asthma in 2019, and it caused 461,000 deaths in the same year. Asthma is commonly prevailed among the children population. The rising pollution levels, extended exposure to harmful gases, exposure to tobacco smoke, fumes, and chemicals are some of the major reasons behind the increasing prevalence of respiratory diseases. As per the World Health Organization, around 90% of the people breathe pollutant air and around 7 million people die every year due to indoor and outdoor pollution. Therefore, the alarming rise in the number of pulmonary diseases and deaths associated with it is expected to spur the demand for the pulmonary drug delivery systems all over the globe.

The surging awareness regarding the pulmonary diseases and the availability of various pulmonary drug delivery devices is supporting the market growth. The easy availability of pulmonary drug delivery devices in the retail pharmacies and the e-pharmacies is expected to have a positive impact on the market. Moreover, the increased research & development activities has encouraged the development of innovative drug delivery systems and the new product launches by the market  players is poised to have a significant effect on the demand for the pulmonary drug delivery systems across the globe. For instance, in October 2018, Philips launched a potable mesh nebulizer named InnoSpire Go. It is a portable, hand-held, and small-sized, and light-weight nebulizer that can administer drugs in just few minutes. Therefore, the presence of top manufacturers and their innovative product offerings are playing a significant role in the market growth.

Scope of the Pulmonary Drug Delivery Systems Market

Report Highlights Details
Market Size US$ 87.53 Billion by 2032
Growth Rate CAGR of 5.60% from 2023 to 2032
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product, Indication, Distribution Channel, Region
Companies Mentioned Philips Respironics, GlaxoSmithKline PLC, BoehringerIngelheim GmbH, TevaPharmaceutical Industries Ltd., 3M Healthcare, PARI GmbH, F. Hoffmann-La Roche AG, Gilbert Technologies, AstraZeneca PLC, Omron Healthcare, Inc.

 

Product Insights

Metered dose inhalers segment garnered a market share of around 66% in 2022 and dominated the global pulmonary drug delivery systems market. The key market players and their innovative metered dose inhalers have gained traction among the consumers and resulted in the dominance of this segment across the globe. The higher product acceptance among the consumers coupled with the increasing rise in the prevalence of pulmonary diseases has fostered the growth of the metered dose inhalers segment.

On the other hand, the nebulizers is expected to be the fastest-growing segment during the forecast period. Nebulizers offers various benefits such as favorable reimbursements, comfort, and easy administration of large doses, which makes it suitable for emergency and at-home use. Hence, this segment is expected to gain rapid traction in the foreseeable future.

Indication Insights

Asthma was the leading segment based on the indication, in 2020. Asthma is a major non-communicable disease that affects both children and adults, as per the WHO. Rapid urbanization and changing lifestyle is a major reason behind the rising prevalence of asthma. The rising awareness regarding the management of asthma and easy availability of the pulmonary drug delivery systems has fueled the growth of this segment over the past years.

The allergic rhinitis is expected to grow at a moderate rate during the forecast period. The surging uses of dry powder inhalers, nasal sprays, and allergy shots for the treatment of allergic rhinitis is boosting the revenues of this segment. Furthermore, the rising prevalence of allergic rhinitis among the population is boosting the growth of this segment.

Distribution Channel Insights

Depending upon the distribution channel, the hospital pharmacy segment dominated the global pulmonary drug delivery systems market in 2022. Hospitals provide quick treatments, east reimbursements, and extensive care, which has contributed towards the dominance of this segment. Moreover, wider availability of the pulmonary drug delivery devices in the hospital pharmacy makes it a popular choice among the patients.

E-commerce is estimated to be the most opportunistic segment during the forecast period. The rising penetration of internet, increasing adoption of smart devices, growing penetration of the online pharmacies across the globe, and quick home delivery services provided by them are the major factors that are expected to drive the growth of this segment in the forthcoming years.

Key Market Developments

  • In April 2019, Glenmark Pharmaceuticals Ltd. introduced to latest inhalers – one metered dosed inhale named Soprobec and another breathe actuated inhaler named Stalpex.
  • In November 2019, Lupin introduced Adhero, a device that tracks the usage pattern of the metered dose inhalers by the COPD patients.

The key market players are constantly engaged in various developmental strategies such as product launches, collaborations, and partnerships in order to establish their supremacy in the market and gain competitive edge over others. These developmental strategies are expected to provide new growth prospects in the forthcoming future and will foster the growth of the global pulmonary drug delivery systems market.

Some of the prominent players in the global pulmonary drug delivery systems market include:

  • Philips Respironics
  • GlaxoSmithKline PLC
  • BoehringerIngelheim GmbH
  • TevaPharmaceutical Industries Ltd.
  • 3M Healthcare
  • PARI GmbH
  • F. Hoffmann-La Roche AG
  • Gilbert Technologies
  • AstraZeneca PLC
  • Omron Healthcare, Inc.

Segments Covered in the Report

By Product

  • Dry Powder Inhalers
  • Nebulizers
  • Metered Dose Inhalers
  • Accessories

By Indication

  • COPD
  • Asthma
  • Cystic Fibrosis
  • Allergic Rhinitis
  • Others

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • E-Commerce

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of Middle East & Africa

Frequently Asked Questions

According to Precedence Research, the global pulmonary drug delivery systems market size was reached at US$ 51 billion in 2022 and is projected to surpass over US$ 87.53 billion by 2032.

The global pulmonary drug delivery systems market is growing at a CAGR of 5.60% from 2023 to 2032.

The global pulmonary drug delivery systems market is primarily driven by the rising prevalence of various pulmonary diseases such as asthma, chronic pulmonary obstructive disease, and allergic rhinitis.

The leading players operating in the global pulmonary drug delivery systems market are Philips Respironics, GlaxoSmithKline PLC, BoehringerIngelheim GmbH, TevaPharmaceutical Industries Ltd., 3M Healthcare, PARI GmbH, F. Hoffmann-La Roche AG, Gilbert Technologies, AstraZeneca PLC, Omron Healthcare, Inc..

North America dominated the global pulmonary drug delivery systems market in 2022. This is attributed to the increased demand for the pulmonary drug delivery devices owing to the increasing prevalence of various pulmonary diseases.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pulmonary Drug Delivery Systems Market 

5.1. COVID-19 Landscape: Pulmonary Drug Delivery Systems Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pulmonary Drug Delivery Systems Market, By Product

8.1. Pulmonary Drug Delivery Systems Market, by Product Type, 2023-2032

8.1.1. Dry Powder Inhalers

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Nebulizers

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Metered Dose Inhalers

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Accessories

8.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Pulmonary Drug Delivery Systems Market, By Indication

9.1. Pulmonary Drug Delivery Systems Market, by Indication, 2023-2032

9.1.1. COPD

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Asthma

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Cystic Fibrosis

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Allergic Rhinitis

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Pulmonary Drug Delivery Systems Market, By Distribution Channel 

10.1. Pulmonary Drug Delivery Systems Market, by Distribution Channel, 2023-2032

10.1.1. Retail Pharmacy

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Hospital Pharmacy

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. E-Commerce

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Pulmonary Drug Delivery Systems Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 12. Company Profiles

12.1. Philips Respironics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. GlaxoSmithKline PLC

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. BoehringerIngelheim GmbH

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. TevaPharmaceutical Industries Ltd.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. 3M Healthcare

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. PARI GmbH

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. F. Hoffmann-La Roche AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Gilbert Technologies

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. AstraZeneca PLC

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Omron Healthcare, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client